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Multi-drug resistance (MDR) is a condition when there is broad cross-resistance of cells to various agents which are different in structure 
and effect. Modern perceptions on mechanisms of MDR development in malignant tumors have been considered, in particular, in tre ating 
breast cancer. Physiological functions and contribution to MDR development of ABC-transporter protein families have been described. 
The role of activation of glutathione system enzymes and apoptosis-regulating proteins in MDR formation has been shown.
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Modern approaches to treating malignant tumors dif-
fer in multimodality and integrity, besides, chemotherapy 
plays an important role among therapeutic methods.
This treatment option significantly loses its topi-
cality due to the presence of multi-drug resistance 
(MDR) of tumor cells, as a result of this phenomenon 
about 90% of treatment cases by cytostatic drugs end 
up in failures [1]. The MDR phenomenon is a condition, 
when there is broad cross-resistance of cells to various 
agents which are different in structure and effect [2, 
3]. MDR was first described by the research group 
of J.L. Biedler in 1970 in experiments with cultivated 
cells [2]. It was discovered that, when treating cell cul-
ture with one drug, a population may be formed which 
is simultaneously resistant to many other substances, 
that cells have never contacted (cross-resistance). 
MDR in vivo may both appear during treatment and 
precede it [4].
Identifying the MDR phenomenon in clinical setting 
is of special importance, since, to reach the cytostatic 
effect, one has to either change treatment regimens 
or carry out aggressive chemotherapy; such treatment 
doesn’t often end up in the necessary outcome and is fre-
quently accompanied by severe complications [5, 6].
MDR is formed by several molecular mechanisms 
which work both independently and together with one 
another, however, usually some mechanism is domi-
nant. In forming drug resistance the mechanism pro-
viding efflux of chemotherapeutic drugs from the cell 
comes to the forefront against the concentration 
gradient with ATP energy consumption, which leads 
to the intracellular drug level falling below therapeutic 
concentrations and which is supported by functioning 
of the ABC-transporter family proteins (ATP-Binding 
Cassette Transporters) [3, 4, 7–10].
The following mechanisms of MDR development 
are also topical: firstly, activation of the glutathione 
system enzymes, which provides tumor cell deto-
xificating superactivity and promotes fast inactivation 
of the chemotherapeutic drug or absence of its activa-
tion; secondly, mutations of the p53 gene or activation 
of bcl-2 gene, which leads to apoptosis cessation 
in response to the cytostatic drug action [3, 4, 7].
THE FAMILY OF ABC-TRANSPORTER 
PROTEINS: STRUCTURE, FUNCTIONS 
AND THEIR ROLE IN DEVELOPMENT 
OF THE MDR PHENOMENON
АВС-transporters are a big family of specific trans-
membrane ATP-binding translocator proteins, carrying 
various low-molecular weight substrates, including 
sugars, aminoacids, proteins, metal ions and different 
hydrophobic compounds [11–14]. In 1993 the research 
group of M.J. Fath suggested classifying more than 
300 proteins of this family into three main groups: eu-
karyotic transporters, bacterial importers and bacte-
rial exporters [15]. About 50 ABC-proteins have been 
discovered in a human organism, however, to date 
it has been proved that genetic evolution of these 
transporters in vertebrata is still continuing [16]. Study-
ing of the evolution and mutation of ABC-transporter 
genes is of great importance for modern science, 
since these proteins influence the functioning of many 
systems in the organism [11, 12, 16, 17]. Changes 
in the structure of genes which code transporters are 
the basis of various pathologies, including disorders 
in cholesterol and bilirubin metabolism, neurological 
disturbances, some hereditary diseases etc.; more-
over, they lead to a failure in penetration of not only 
exogenous, but also natural anti-tumor compounds, 
which are analogues of nucleosides, antimetabolites 
and tyrosine kinase inhibitors, into the cell [11, 12, 
17–19].
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АВС-transporters are divided into 7 subfamilies 
marked as ABCA, ABCB, ABCC, ABCD, ABCE, ABCF 
and ABCG [13, 20]. The structure of all representatives 
of the family is quite conservative and is united under 
domain organization, containing various combinations 
of two functional subunits: transmembrane  binding 
domain (ТMD) or MSD-transmembrane subunit, which 
consists of six helices, and nucleotid binding domain 
(NBD) — a subunit including two domains. NBD do-
mains are called Walker A, it is bound to the phosphoric 
acid residual of the ATP molecule. The second do-
main — Walker B domain — contains asparagine acid 
and is bound to magnesium associated with nucleo-
tides [13, 21–23]. All ABC-transporters are divided into 
full and half transporters according to their structure. 
Full transporters are characterized by the (TMD-
NBD)2 structure and are located in the cell membrane. 
Transporters with the TMD-NBD structure are called half 
transporters; they are usually located in the intercellular 
membranes (lysosomal, mitochondrial membranes, 
endoplasmic reticulum), the only exception being 
the ABCG2 half protein (alias BCRP — breast cancer 
resistance protein), which can be also located in the cell 
membrane [23, 24].
Prokaryotic and eukaryotic proteins of this family 
are 30–40% homologous according to the NBD subunit 
structure, regardless of the transported substrates [22].
In terms of chemical mechanisms, broad substrate 
affinity of ABC-transporters hasn’t been explained for 
a long time. At present it is supposed that formation 
of the so-called “inner pocket” underlies the ABC 
transporter functioning [3, 22, 25]. Such mechanism 
has been first suggested by Neyfakh, who investi-
gated the functioning of a small bacterium protein, 
which was named BmrR [26]. The researchers found 
out that, when binding this protein to the substrate, 
the alpha-helix of the ligand-binding domain, conta-
ining negatively charged gluthamine residue, unwinds 
(thus, forming “the inner pocket”); after that positively-
charged ligands bind to this residue.
In clinical oncology research of expression and 
activity of ABC-transporters is aimed at eliminating 
disorder in toxic xenobiotic metabolism in tumor cells, 
i.e., the MDR phenomenon. From this point of view 
it is topical to study not all transport proteins, since 
mutations in genes coding the ABCD subfamily pro-
teins are the basis of solely hereditary peroxisomal 
diseases [23]. ABCE and ABCF subfamilies include 
proteins containing one set of TMD-NBD; they are 
located in intracellular membranes and are not involved 
in MDR development [17].
Nowadays the ABCA subfamily is the most studied 
one, however, despite the fact that it includes the big-
gest amount of human ABC-transporters — 12 repre-
sentatives — ABCA2 is the only protein of the subfamily 
that contributes to development of MDR to chemothe-
rapy [23, 27]. Overexpression of ABCA2 in tumor cells 
gives them resistance to estramustine — an alkylating 
agent used in chemotherapy of prostate cancer [28].
The ABCB, ABCC and ABCG subfamilies are 
of the greatest research interest in clinical oncology 
in terms of MDR development in breast cancer (BC). 
Contribution of these subfamilies to the development 
of resistance to chemotherapy has been proved for 
malignant tumors of various localization: lung cancer, 
colon cancer, bladder cancer, prostate cancer as well 
as in leukemia, myeloma and sarcomas [9, 13, 29–39]. 
Nowadays development of targeted drugs directed to se-
lective inhibition of tumor ABC-transformers is an urgent 
task [40, 41].
The role of the ABCB subfamily in emergence 
of resistance to chemotherapy. The ABCB subfamily 
(another name for the MDR subfamily) includes 11 pro-
teins. Its representatives may be both full transporters 
(ABCB1 or Pgp, ABCB4, ABCB11), located in the apical 
part of the cell membrane and half transporters (ABCB2, 
ABCB3, mitochondrial membrane transporters ABCB6, 
ABCB7, ABCB8 and ABCB10 as well as lysosomal 
membrane transporter ABCB9) [23].
The ABCB1 protein (Р-glycoprotein, Pgp) is a big 
transmembrane protein with the molecular weight 
of 170 kDa; it is the largest studied representative 
of the ABC-transporter family which is involved in de-
veloping resistance of tumor cells to chemotherapy. 
Since the interrelation between membrane transporter 
proteins and MDR was first demonstrated when stu-
dying P-glycoprotein, MDR, determined by overex-
pression of the stated protein, is also called typical 
or classic [3]. The protein was discovered in the mem-
brane of resistant cells in the research laboratory 
by the research group of Juliano and Ling in 1976 [42].
Human Pgp is coded by the MDR1 gene, located 
on the chromosome 7 (7q21.1); besides, resistance 
development may follow both a change in MDR1 gene 
expression and amplification of the genome part 
containing the MDR1 gene and five-six other genes 
coupled with it [43–45]. Mechanisms of resistance 
development were studied in some research on in-
vestigating specially selected resistant Cerb-1 and 
Cerb-2 sublines as well as the CHLV-79RJK line 
of Chinese hamster cells [43, 44].
The MDR1 gene has two promoter regions — 
lower and upper promoters; gene activity is mostly 
regulated by the lower promoter [46]. Transcription 
activity of MDR1 rises in response to different impacts, 
including the effect of chemotherapy drugs (also 
the ones that are not Pgp substrates) [47]. Moreover, 
MDR1 activity may be influenced by р53, ras, raf, RAR-
alpha and RAR-beta genes (genes of retinoid acid 
receptors) [3, 48] as well as genes of с-fos and c-jun 
transfactors [3, 49]. Supposedly, protein kinase C, pro-
tein kinase A and other protein kinases also take part 
in regulation of Pgp activity [50]. Taking into account 
multi-activity of MDR1/Pgp, it may be concluded that 
this transport system is extremely necessary for nor-
mal cell functioning; that is why its regulation is more 
than once repeated [3].
Pgp is a polypeptide which consists of two similar 
parts. Each part includes six hydrophobic transmem-
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brane regions which cross the cell membrane 12 times, 
thus, forming pores and canals, by means of which Pgp 
releases substances, using ATP hydrolysis ener gy from 
two binding sites in NBD domains [3, 25]. When dyed 
by monoclonal antibodies, predominant ABCB1 loca-
lization is found on the surface of the cell membrane; 
small amount of ABCB1 are located in the area of Golgi 
complex [3, 51].
Prominence of Pgp expression in different tissues 
is not even; high values are found in tissues which actively 
contact xenobiotics: liver, kidneys, mucous membranes 
of the large and small intestine, adrenal tissue, brain ca-
pillary endothelium, testicles, placenta trophoblast [32]. 
Extremely low level of protein expression is also found 
in the lungs and epidermis cells. In the bone marrow 
CD34-positive cells express functionally active Pgp [50], 
then, as cells of the myeloid type become mature, the ex-
pression and functional activity of this protein gradually 
decrease [35]. Tumors originating from Pgp-expressing 
cells will have pre-existing MDR.
The physiological role of ABCB1 is to protect 
from xenobiotics and export of endogenous metabo-
lites [52, 53]: presence of P-gp in the intestinal epithe-
lium prevents toxic substances entering the organism; 
its expression in renal tubules and the canalicular 
membrane of hepatocytes ensures their elimination 
from the organism. Рgp is overexpressed in the epithe-
lium of the brain choroid plexus, which indicates its role 
in forming the blood-brain barrier [54]. P-glycoprotein 
located in the placenta trophoblast not only plays 
a significant role in limiting the effect of drugs and 
toxins on the fetus, but it is also necessary for normal 
development of the placenta and for maintaining its 
physiological functions [52].
Pgp is to a different extent expressed in all types 
of tumors. Tumors that are characterized by overex-
pression of the MDR1 gene are carcinomas of the large 
intestine and kidneys, hepatomas, renal tubule 
cancer, pheochromocytomas. In adenocarcinomas 
of the lungs and testicles, BC and sarcomas emer-
gence of acquired MDR has been proved, which 
is determined by a rise in Pgp expression during 
chemotherapy or which is associated with genomic 
instability of malignant cells [55–58].
Pgp enhances tumor resistance to taxanes, podo-
phyllotoxins, alkaloids of plant origin, including vinca al-
kaloids, antracyclic antibiotics and other chemotherapy 
drugs. Besides, this protein ensures fast elimination 
of many other substances: ethydium bromide, fluores-
cent dyes, gramicidin D, puromycin etc. [3, 44].
Pgp-mediated MDR is characterized by a decrease 
in cell resistance to chemotherapy drugs under the ef-
fect of MDR modulators or inhibitors [59]. Inhibitors 
are membrane-active low molecular weight lipophilic 
substances similar in their chemical compositions: 
calcium channel blockers (CCB) (nifedipine, vera-
pamil and its analogues), trifluoroperasine, quinine, 
representatives of the acridine group, indole alkaloids 
(including reserpine and yohimbine), some antibiotics 
(cephalosporin, gramicidin, puromycin) and other [1, 
50, 60]. Highly-efficient inhibitors discovered in the last 
years are А PSC833 (the analogue of cyclosporine) and 
the carboxamide derivative GG918 [60].
One of the mechanisms of inhibitor action is com-
petition with cytotoxic agents for binding to Рgp (for 
example, in case of verapamil). The problem lies 
in the fact, that all the above-mentioned MDR modula-
tors have been discovered in experiments in vitro in cell 
cultures, their use in clinical practice is impossible 
at this stage. The research has shown that for the ma-
jority of inhibitors it failed to obtain the concentrations 
in blood of patients that are necessary to overcome 
drug resistance, since a rise in dose gives severe 
complications [60].
In recent years new therapeutic approaches have 
been actively searched, such as the use of mono-
clonal antibodies to Pgp as MDR modulators and 
regulation of ABCB1 expression with help of epigenetic 
modulators (for instance, inhibitors of histone deacety-
lases — HDACi); nowadays clinical trials are being car-
ried out [56, 61].
The role of the ABCC family in emergence 
of resistance to chemotherapy. This group includes 
13 representatives which are full transporters; the ma-
jority of them (АBCC1–6, 10, 11) are active transmitters 
of various organic anions in hydrophobic drugs, there-
fore, they are involved in MDR development [11, 12].
The ABCC7, ABCC8 and ABCC9 proteins don’t par-
ticipate in MDR development, however, they perform 
important functions of sustaining normal cell metabo-
lism. The ABCC7 protein (CFTR) functions as an anion 
channel; it regulates their flow in epithelium cells. 
In case of mutations in the gene coding this transporter, 
cystic fibrosis develops [11, 12]. The АBCC8 (SUR1) and 
АBCC9 (SUR2) proteins, which are receptors of sul-
fonylurea [62], regulate permeability of ATP-specific 
potassium channels (Kir 6.2 and Kir 6.1, respectively). 
Mutations in genes that code these proteins may serve 
a reason for decreased tolerance to glucose [63].
The thirteenth family representative — АBCC13 — 
was discovered most recently; it was cultivated from 
cells of the liver, fetus and placenta, and its structure 
and functions are yet to be studied [11, 12].
A group of the ABCC family proteins, which deter-
mine MDR development, is united under a common 
name — multidrug resistance-associated protein (MRP) 
and includes nine members. MRP are transporters 
of organic anions (except for MRP9, which function 
has not been identified yet); consequently, they trans-
port anionic drugs, such as methotrexate, and neutral 
drugs conjugated to acid residues, such as glutathi-
one, glu curonate and sulfate. However, MRP1, MRP2, 
MRP3 may also cause resistance to neutral organic 
drugs, which don’t form conjugates to acid residues [11, 
12, 33, 64].
Six main representatives of MRP proteins (MRP1–6) 
are divided into two groups. MRP1, MRP2, MRP3 and 
MRP6 have the external N-terminal domain (marked 
as TMD0), which Pgp lack. MRP4, MRP5 don’t have 
the TMD0 domain, the degree of similarity of these 
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proteins to MRP1 is less than 40% [33]. Nevertheless, 
they are more homologous than P-gp or other classes 
of ABC-transporters. Besides, research has shown 
that TMD0 is not necessary for transport activity [65].
The most well-studied representatives of MRP are 
the ABCC1 and ABCC2 proteins. The ABCC1 pro-
tein or MRP1 was discovered in 1992 by Cole et al. 
in lung cancer cell lines resistant to doxorubicin [72]. 
It is a transmembrane protein located on the basola-
teral cell surface. Preferable substrates for MRP1 are 
organic anions, i.e., drugs conjugated to glutathione, 
glucuronate or sulfate [31, 34]; it is one of the main 
transporters of glutathione conjugates [66]. It is a pro-
tein with the molecular weight of 190 kDa, which gene 
is located on the chromosome 16 (16p13.1). It has 
five transmembrane segments in MSD2 and four-six 
transmembrane segments in MSD3 [67, 68].
MRP1 is widely expressed in epithelial cells 
of the organism, including digestive, urogenital and 
respiratory systems, in endocrine glands and hema-
topoietic organs, including all peripheral blood cells, 
regardless of their differentiation [30, 33, 36, 39]. 
Some resear chers consider overexpression of the pro-
tein in bronchial epithelium as one of the reasons for 
bronchial asthma development [36].
High expression level of this protein has been 
detected in many tumor cells in lung cancer, colon 
cancer, BC, bladder cancer, prostate cancer as well 
as in leukemia [30, 69–71]. MRP1 plays an important 
role in cell MDR to etoposide, antracyclic antibiotics, 
vinca-alkaloids, stibium and arsenium drugs [72] 
as well methotrexate [33, 73].
Nowadays effective and safe MRP1 modulators 
are being searched. As potential MRP inhibitors LTC4, 
LTD4 and S-decylglutathione [74] are considered 
along with organic acids, originally developed for 
suppression of uric acid transport: sulfinpyrazone, 
benxbromarone and probenecid [75].
The ABCC2 (MRP2, cMOAT, cMRP) protein was 
first discovered in the hepatocyte cell membrane; due 
to this fact it was named canalicular multispecific or-
ganic aniontransporter (cMOAT) [76]. MRP2 is a trans-
porter of bilirubin glucuronides in bile; gene mutations 
or a decrease in expression of this protein are known 
as the Dubin — Johnson syndrome [77].
ABCC2 expression is also identified in cells 
of proximal kidney tubules and intestinal epithe-
lium. The MRP2 gene is located on the chromosome 
10 (10q24). According to its domain organization it re-
sembles MRP1; it is also a transporter of substances 
conjuga ted to glutathione, glucuronic and sulfuric 
acids [13].
At present active research is being carried out 
on studying the link between MRP2 expression and 
the course of BC. By the immunohistochemical analy-
sis it has been shown that two types of ABCC2 proteins 
are identified: the one located in the cell membrane 
and tumor cell cytoplasm (ABCC2c) and the one lo-
cated in nuclear envelope of atypical cells (ABCC2n). 
According to the research results it may be concluded 
that tumors with overexpression of the protein in both 
locations are characterized by a worse forecast. 
If the protein is located in the nuclear envelope, tumors 
have more aggressive clinical presentation of the di-
sease compared to cases when ABCC2 are located 
on the cell membrane [29].
MRP2 may be the cause of tumor cell resistance 
to methotrexate, cisplatin, etoposide, doxorubicin, 
epirubicin, vincristine and mitoxantrone [29, 72, 
78]. On the whole the range of resistance coincides 
with the one in MRP1 with one exception: MRP2 in-
duces resistance to cisplatin, which is not observed 
in MRP1 [78, 79].
Now effective inhibitors of ABCC2 are being 
searched; though MRP1 and MRP2 have similar sub-
strate specificity, MRP1 inhibitors are not necessarily 
effective with respect to MRP2; for example, sulfin-
pyrazone is applicable only for ABCC1 therapy [33].
АBCC3 (MRP3, MOAT-D, cMOAT-2, MLP-2) is also 
a transporter of organic anions; however, as opposed 
to MRP1 and MRP2, it prefers glucuronates to gluta-
thione conjugates [45, 80]. The MRP3 gene is located 
on the chromosome 17 (17q21.3), it codes protein 
expressed in norm in the epithelium of the large and 
small intestine, hepatocytes, pancreas, adrenals and 
lungs [11, 12, 64].
When studying the cell culture and the histological 
material from patients with lung cancer, MRP3 expres-
sion determines a decrease in sensitivity to etoposide, 
doxorubicin, vincristine and cisplatin. In the meantime, 
no direct link between MRP3 overexpression and tumor 
prognosis has been observed [81]. These cells are also 
resistant to short-term effect of methotrexate [82].
АBCC4 (MRP4, MOAT-B) is a specific trans-
porter of conjugates to phosphorous acid residues 
(analogues of nucleosides); but it can also transport 
glutathione, glucuronides and sulfates. The gene co-
ding MRP4 is located on the chromosome 13 (13q32). 
The MRP4 structure differs from that of MRP1, 
MRP2 and MRP3 in the absence of the NH2-terminal 
domain MSD (TMD0) [79]. Schuetz et al. [83] have 
found out that MRP4 eliminates drugs for HIV treat-
ment from the cell: 9-[2-(phosphono metoxi)ethyl]
adenine (PMEA) and azidothymidine monophosphate 
(AZTMP) in cells that are resistant to PMEA. High level 
of MRP4 is also a reason for severe drug resistance 
of cells to some nucleoside analogues, including 
9-[2-(phosphono metoxi)ethyl] guanine, which has 
antitumor activity. Moreover, tissues with MRP4 over-
expression have short-term resistance to methotre-
xate, as MRP3 [84]. Lai et al. have established that 
glutathione plays an important role in MRP4 functi-
oning; depletion of its intracellular reserves decreases 
cell resistance to nucleoside analogues [85].
The gene coding ABCC5 (MRP5, MOAT-C, pABC11, 
sMRP) is located on the chromosome 3 (3q27), high 
expression of this transporter has been detected 
in many tissues of the organism, especially in the mus-
culoskeletal system and in the brain [79]. Overexpres-
sion of MRP5 leads to resistance to thiopurines, such 
148 Experimental Oncology 36, 144–156, 2014 (September)
as 6-mercaptopurine and tioguanine, which are used 
to treat acute lymphoblastic leukemia and acute my-
eloid leucosis, and to PMEA [33]. McAleer et al. [86] 
also found that accumulation of anionic fluorochromes 
decreases in MRP5-transfected cells; they acquire 
resistance to heavy metals. Research has demon-
strated that MRP5 may be inhibited by sulfopyrasone 
and benzbromarone [87].
The АВСС6 gene (MRP6, MOAT-E, MLP-1, ARA) 
is located on the chromosome 16 (16p13.1); high level 
of MRP6 expression has been detected in the liver 
on the lateral hepatocyte membrane and in the kid-
neys [82]. The physiological role of this protein 
is unclear. To date it has been known that deletions 
and other mutations in the gene, coding this protein, 
lead to development of pseudoxanthoma elasticum, 
a disease that is characterized by disorder in forma-
tion of yellow fibers accompanied by skin, eye and 
cardiovascular lesions [88].
Belinsky et al. [89] have analyzed the contribution 
of MRP6 to MDS: in MRP6-transfected cells low level 
of resistance to anthracyclic antibiotics and podophyl-
lotoxins (etoposide, tenyposide) is observed.
Interestingly, overexpression or full/partial ampli-
fication of the MRP6 gene was found only in cell lines 
with MRP1 overexpression/amplification. It is likely 
that MRP6 doesn’t play a significant role in tumor 
cell resistance, and its expression together with 
MRP1 is explained by close proximity of their genes 
on the chromosome 16 [82, 90]. Amplification of 3-end 
of the MRP6 protein is of great importance in cell 
MDR of patients with acute myeloid leukemia; ear-
lier this MRP6 region was called ARA (anthracycline 
resistance-associated protein) [91].
ABCC10 (MRP7) is a protein with the molecu-
lar weight of 158 kDa, coded by the gene located 
on the chromosome 6 (6p12–21). It has been dis-
covered relatively recently in reticulocyte lisates; its 
extremely low expression was detected in other tissues 
as well; its physiological role is currently unknown [92].
ABCC11 or MRP 8 is a protein with the molecular 
weight of 150 kDa, which gene is located on the chro-
mosome 16 (16q12.1). In normal tissues moderate 
protein expression is observed in the testicles and 
the liver. The MRP8 structure is close to that of MRP5: 
homology is 42% [93].
The research by Bera et al. [94] determined high 
level of MRP8 expression in tumor tissues of patients 
with BC. The MRP8 gene codes two different RNA 
transcripts: 4.5-kb and 4.1-kb. In the meantime, 
4.5-kb transcript was detected in breast tumors, 
whereas 4.1-kb — in testicle cells. The physiological 
role and the contribution of this transporter to develop-
ment of BC as well as resistance to pharmacotherapy 
is currently unknown [93, 94].
The ABCC12 (MRP9) protein was identified 
by two research groups — Bera et al. [94], Tam-
mur et al. [93] — in tumor cells of patients with 
BC. The MRP9 gene, located on the chromosome 
16 (16q11), also codes two different mRNA transcripts 
(4.5-kb and 1.3-kb transcripts), which are expressed 
in various tissues in a different way: 4.5-kb transcript 
was detected in tumor tissue in BC and in normal 
tissues of the breast and the testicles, whereas 
the 1.3-kb transcript was found in brain tissues, ske-
letal muscles and testicles [95]. The physiological role 
of MRP9 and its contribution to MDR emergence are 
currently not determined.
The role of the ABCG family in emergence 
of resistance to chemotherapy. Five human pro-
teins of this group are described; they are represented 
by half membrane transporters located in the cell 
membrane. This differentiates them from other half 
transporters situated in intracellular membranes [96].
It is proved that mutation of genes that code 
ABCG5 and ABCG8 leads to development of rare 
autosome-recessive pathology — р-sitosterolemia, 
which is characterized by accumulation of plant sterol 
in blood and tissues [97].
The main physiological role of the ABCG1 protein 
is support of lipidic homeostasis in organism tissues, 
especially in the lungs, central nervous system and 
vessels [96, 98–100]. Besides, this protein partici-
pates in secretion of insulin by pancreas β-cells [98, 
100–102], controls proliferation of hematopoietic stem 
and multipotent precursor cells both in the bone mar-
row and spleen in case of extramedullary hematopoi-
esis [100, 103]. ABCG1 malfunction leads to develop-
ment of atherosclerosis, excess accumulation of lipids 
in macrophages and formation of foam cells [98, 99, 
104]. Mutations of the gene coding the ABCG1 protein 
are accompanied by risk of type II diabetes deve-
lopment [101, 102]. The role of this protein in MDR 
development is unclear, however, in 2012 V. Hlaváč 
et al. compared breast tissue samples before and after 
neoadjuvant therapy and found out that after therapy 
expression of ABCG1 rises [105].
The ABCG2 protein has been described to the 
ful lest extent, it is the only representative of the fam-
ily, which overexpression is proved to cause MDR 
deve lopment [96]. This protein was first discovered 
by the research group of L.A. Doyle in 1998, when 
studying the MCF-7 cell line of BC; it was named 
BCRP. The stated protein was also identified in other 
research, it has interchangeable names MXR (mito-
xantrone resistance protein) and ABCP (placental ABC 
transporter) [106–110].
BCRP is a protein with the molecular weight 
of 72.6 kDa, its coding gene is located on the chromo-
some 4 (4q22) [111]. High expression of this protein 
is marked in the placenta, myocardium, testicles and 
endothelium of vessels [111, 112]. Medium level of ex-
pression is found in the liver, large and small intestine, 
brain and prostate; low expression during histochemi-
cal studies has been discovered in the lungs, skeletal 
muscles, pancreas, kidneys, spleen, thymus, multi-
layered skin and esophagus epithelium and peripheral 
blood leukocytes [106, 112, 113].
Physiological functions of BCRP lie in providing tis-
sue protection from endogenic toxins or xenobiotics and 
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regulating cell homeostasis of physiologically important 
compounds such as heme, porphyrin, riboflavin and 
estrogens [114–116]. ABCG2 plays the key role in folic 
acid homeostasis, which may promote cell survival 
in conditions of hypoxia [108]. Besides, much research 
has shown that high expression of this protein is marked 
in primitive stem cells of human bone marrow, which 
ensures protection of these cells from xenobiotics [109].
Research of BCRP expression in normal tissues 
that was carried out by Doyle and Ross [113] proved 
an extremely high level of ABCG2 in the placenta 
(in particular, in syncytiotrophoblast and on the apical 
surface of chorionic villi) — about 100 times higher 
than in other tissues with high expression of this pro-
tein. This fact suggests that BCRP plays a particular 
role in protecting the fetus from toxic substances [52].
Many researchers believe that this transporter 
performs a protective function as part of the blood-
brain barrier due to high expression in the endothelium 
of brain vessels [106–108, 117].
In tumor cell lines a high level of ABCG2 has 
been detected in BC, colon cancer, stomach and 
lung cancer, myeloma and sarcomas [13, 118–120]. 
ABCG2 of mRNA has also been identified in blast 
cells of patients with acute myeloid leukemia resistant 
to chemotherapy [121, 122].
It has been proved that overexpression of BCRP 
promotes resistance of tumor cells to mitoxantrone, an-
tracyclic antibiotics (in particular, doxorubicin), methotre-
xate, camptothecin derivatives (topotecan, SN-38) and 
indolocarbazole derivatives. In the meantime, resistance 
to antracyclic antibiotics is unstable and is probably con-
nected with the presence of mutation in the 482 codon 
of the gene coding BCRP [109, 113, 123–126].
At present effective specific inhibitors of BCRP are 
being searched, the influence of tyrosine kinase inhibi-
tors as well as a number of antiviral drugs, used for 
HIV treatment, statins and imatinib on the transporter 
function is studied [106, 109, 124]. At the moment 
a whole class of new compounds synthesized from 
XR9576 (tariquidar) has been received, which selec-
tively inhibit BCRP [110].
THE ROLE OF ACTIVATION OF GLUTATHIONE 
SYSTEM ENZYMES IN EMERGENCE OF MDR
Glutathione (GSH) is a tripeptide which is synthe-
sized in the organism from glutamic acid, cycteine 
and glycin; it performs detoxificating, antioxidant and 
immunoprotective functions. The action of glutathione 
is ensured (carried out) by its conjugation in various 
electrophilic substances; this process is catalyzed 
by glutathione-S-transferases (GSTs) [127, 128].
GSTs are found in all mammals and plants. They 
may exist as homo- and heterodimers with the mo-
lecular weight of 43–57 kDa, each subunit has its own 
independent binding site, which, in turn, contains 
two subsites: G and H. The former interacts with glu-
tathione (contains protein –SH group, histidine and 
arginine); the latter binds the hydrophobic substrate, 
it contains glycine. According to identity of the ami-
noacid composition, GSTs in mammals are grouped 
in six classes: α- (alpha-), μ- (mu-), κ- (kappa-), 
θ- (theta-), π- (pi-) and σ- (sigma-) GST. In human 
organism mostly four main GST classes are expressed: 
GSTA (α-class), GSTM (μ-class), GSTT(θ-class) and 
GSTP(π-class) [127, 129]. Glutathione transferases 
are mainly located in the cytosol and endoplasmic 
reticulum, however, they may be found in nuclei and 
mitochondria as well.
Representatives of the GSTA class are widely ex-
pressed almost in all tissues of the organism; they are 
the main representatives of glutathione transferases 
in the liver. The GSTM class includes five genes with 
different expression localization: GSTM1 is expressed 
in blood and liver cells, GSTM2 — solely in muscles, 
GSTM3 and GSTM4 — in cells of the central nervous 
system, GSTM5 — in cells of the central nervous sys-
tem, liver, testicles and to a smaller extent — in trans-
verse cardiac muscles. Glutathione transferases 
of the theta-class are located in erythrocytes and cells 
of the liver. The GSTP class, as the only representative 
of GSTP1, is also widely spread in cells of the orga nism 
as well as alpha-class representatives, but it lacks 
in erythrocytes; its highest expression is marked 
in cells of the placenta and skin [127, 129, 130].
Recently it has been discovered that the GSTs 
system not only promotes detoxification of xenobio-
tics and cancer-inducing substances, but also acts 
as a modulator of the pathway which transmits signals 
that control cell proliferation and apoptosis [127, 130].
Multifunctional family of glutathione-S-transferase 
also plays an important role in catechol estrogen 
metabolism. In case of catechol estrogens GSTs act 
as a detoxificating agent, promoting conjugation 
of genotoxic estrogen metabolites to glutathione, 
which, as well as conjugation to N-acetylcycteine 
and cycteine, causes their inactivation [131–134]. 
In some research it has been shown that there 
is a link between GSTs gene polymorphism and risk 
of BC development. In the so-called zero genotype 
of GSTs, which is characterized by low enzyme activity, 
risk of BC development was 2.1 times higher in pre-
menopausу and 2.5 times higher in post-menopause, 
and in case of zero genotype combined with low acti-
vity of ca techol-O-methyl transferase it was 3.5 times 
higher [132, 135].
Disorders in glutathione system metabolism 
in the human organism may be the cause of ma-
lignant tumor development. A rise in GSTs activity 
in tumor cells results in development of resistance 
to a number of chemotherapy drugs [136]. Thus, ac-
cording to the carried out research, high concentration 
of glutathione has been detected in cell lines resistant 
to alkylating agents (embichine, chlorbutin, melpha-
lan, cyclophosphamide etc.) and other drugs [3, 132, 
137, 138].
The role of glutathione system activation in deve-
lopment of drug-resistance was demonstrated when 
studying the level of GSH and GSTs in P 388 leukemia 
cells resistant to cycloplatam. The level of glutathi-
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one was almost 10 times higher compared to parent 
cells of this line, whereas glutathione transferase 
activity was 1.5 times higher in cells of the resistant 
strain as opposed to the sensitive one. Cycloplatam 
administered to tumor carrying mice has caused 
a significant increase in the level of GSH in tumor 
cells of both strains. The obtained results indicate that 
GSH-dependent enzymes may significantly contribute 
to drug resistance of cells [139]. Thus, the role of MDR 
development associated with glutathione transferase 
activation in brain tumors has been proved [140].
When studying changes in the glutathione system, 
emergence of resistance has been proved not only 
to alkylating agents, but also to antracyclic antibiotics 
and vincristine (drugs of Pgp-MDR), which suggests 
existence of general mechanisms of regulation of ABC-
transporter genes and genes involved in glutathione 
metabolism [139].
The research group of C.S. Morrow [141] has shown 
that overexpression of PGP and a rise in GST acti vity 
are identified in the MCF7 cell line of BC resistant 
to 4-nitroquinoline-1-oxide (4-NQO). In the meantime, 
such combination is associated with GST-dependent in-
crease in formation of 4-NQO-glutathione-conjugates, 
which are eliminated from cells by Pgp [141, 142].
Many types of malignant tumors contain the in-
creased amount of glutathione in tissues and have 
high activity of glutathione transferases, which allows 
their cells to increase resistance to chemotherapy right 
up to MDR formation. At present a number of drugs 
inhibiting GSTs selectively in tumor cells are being de-
veloped; their use in combination with cytostatic drugs 
should increase the efficiency of anti-tumor therapy. 
Inhibitors are also considered as one of the potential 
therapeutic approaches to treating other diseases 
related to aberrant cell proliferation [143, 144].
THE LINK BETWEEN CHANGES 
IN APOPTOSIS-CONTROLLING GENES 
AND EMERGENCE OF MDR
Nowadays the mechanism of MDR development re-
lated to apoptosis suppression is paid more and more 
attention to, since the cytostatic effect of the majority 
of drugs is realized by induction of this very pathway, 
regardless of a certain mechanism of action of every 
drug. The key role in apoptosis is played by functional 
activity of TP53 and bcl-2 genes as well as their protein 
products [7, 145–149].
Mutation of the ТР53 gene and development 
of the MDR phenomenon. During cell tumor trans-
formation and tumor progression one of the most com-
mon changes is mutation of the TP53 tumor in the sup-
pressor gene [150–152]. In norm the TP53 gene 
is activated in response to various cell damaging fac-
tors; in the meantime, the wild type of the p53 protein 
is synthesized, which leads to a stop of the cell cycle 
and (or) facilitates cells entering apoptosis [153, 
154]. In defective cells conditions for damaged DNA 
reparation emerge, otherwise cells are removed from 
the population. Cells where normal p53 lacks are resis-
tant to apoptosis induction [155]. The p53 mutagenic 
protein demonstrates the properties of an oncogene, 
since it doesn’t have the ability to stop cell division 
at the key points of the cell cycle, which results 
in the beginning of DNA replication in cells on the da-
maged matrix. It promotes instability of the genome 
and development of malignant transformation [156, 
157]. Therefore, tumor cells with mutant ТР53 are re-
sistant to the action of alteration factors, which include 
cytostatic drugs [3, 158].
It has been proved that stromal cells of malignant 
epithelial tumors, in particular, fibroblasts with un-
changed suppressor gene р53, are able to produce 
and secrete tumor inhibiting factors [159, 160].
Inductors causing the wild type of p53 are a com-
bination of agents that cause DNA damage in different 
ways, for example, by changing the redox-potential 
(in particular, during accumulation of reactive oxygen 
species) or the nucleotide pool in the cell, which leads 
to destruction of the mitotic spindle of cell division 
etc. [153, 161]. Due to this fact malignant tumors with 
the mutant р53 are typically resistant to drugs with 
diffe rent mechanism of action (for instance, to cisplatin 
and 5-fluorouracil) [3].
There are also many facts proving that the p53 pro-
tein participates in regulation of ABCB1 action. It has 
been shown that the wild type of p53 suppresses and 
the mutant p53s protein increases ABCB1 activity [48, 
56, 158]. Besides, when studying MDR of rhabdomyo-
sarcoma and neuroblastoma cell lines, it has been 
found out that p53 is a strong inhibitor of P-glyco-
protein and ABCC1 (MRP1) functions [56, 57]. When 
studying MDR of prostate cancer, the correlation be-
tween a decrease in the degree of tumor differentiation 
and a rise in MRP1 expression has been identified. 
A combination of these two mechanisms resulted 
in development of tumor resistance to doxorubicin 
and vinblastine [57, 162, 163].
Therefore, functional recovery of the wild type 
of p53 may be the strategy for reducing or preventing 
MDR; it may also help increase sensitization of cancer 
cells to anti-tumor drugs [56, 153, 154, 164, 165].
The Bcl family of proteins and its influence 
on emergence of resistance to chemotherapy. 
Besides tumor suppressors, malignant tumor sensiti-
vity to various xenobiotics is influenced by antiapop-
totic proteins. The leading role in this process is given 
to the Bcl family proteins [166]. Functions of proteins 
of this family are directly opposite to one another; 
the bcl-2 gene codes proteins having both antiapoptotic 
(BCD-XL, Bag, Bcl-2) and proapoptotic (Bcl-xS, Bax, 
Bad, Bak, Bid) effects on cells [133, 167, 168].
It was proved that during Bcl-2 overexpression 
tumor cells have drug resistance to various cytostatic 
drugs [169]. There are data indicating that expression 
of the bcl-2 gene may be referred to markers of drug 
resistance to chemotherapy in a number of malignant 
tumors: bladder cancer, prostate cancer, testicular 
cancer, myeloid and lymphoid tumors of the hemato-
poietic system, brain tumors [130, 170, 171].
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Clinical studies have detected the interrelation 
between the expression level of antiapoptotic genes 
bcl-2 and bcl-xL in various tumors and their high re-
sistance to chemotherapy drugs [172, 173]. However, 
in lung and BC one can’t say for sure about the cor-
relation between bcl-2 overexpression and resistance 
to chemotherapy, since expression of antiapoptotic 
proteins Вс1–2 and Bcl-xL occurs in cells of these 
tumors alongside with expression of the Bax pro-
apoptotic protein [145, 173–177]. The Вс1–2 and Вах 
proteins form heterodimers inactivating the action 
of the antioncogene; consequently, the proportion 
of these proteins in the cell determines its predisposi-
tion to apoptosis and chemotherapy drug action [145, 
176]. In the work by Sumantran et al. intensification 
of induced apoptosis has been detected in the trans-
fected cell line of BC MCF-7 in response to etoposide 
and taxol [178]. According to the latest research, over-
expression of Bcl-2 that occurred after first-line chemo-
therapy of BC suggests MDR development in response 
to therapy [55, 173, 179, 180].
Proapoptotic proteins bcl-2 have a domain in their 
structure called BH3, its binding by antiapoptotic 
proteins bcl-2 leads to apoptosis suppression [181]. 
Compounds that inhibit this bound induce apoptosis 
on their own or in synergism with other cytostatic 
chemotherapy drugs. Recently a whole range of such 
drugs has been developed, however, further research 
has shown that many assumed inhibitors are not 
specific and have other cell targets [181–184]. There 
are two exceptions to this: for instance, ABT-737, its 
successful application as the only drug agent for treat-
ment of leukemia and lung cancer has been proved. 
The second drug is ABT-263; at present it is at the stage 
of clinical trials for treating small-cell lung cancer, lym-
phatic leukemia and lymphoma [185, 186].
In conclusion it should be said that disorder in regu-
lation of genes that are involved in apoptosis control 
(oncosuppressor р53 and genes of the bcl-2 family) 
may lead to cells developing resistance to a wide range 
of anti-tumor drugs — DNA-tropic agents (adriamycin, 
actinomycin D), antimetabolites (5-fluorouracil), but 
not to the compounds interacting with mitotic spindle 
of cell division (colchicine, taxole) [187–191].
CONCLUSION
Nowadays one of the leading methods of treating 
malignant tumors is chemotherapy, both non-adjuvant 
and adjuvant. This therapy is significantly losing its 
topicality due to the presence and (or) development 
of MDR. In the mechanism of MDR development activa-
tion of ABC-transporter proteins and glutathione system 
enzymes as well as changes in apoptosis-controlling 
genes plays the key role. Therefore, determination 
of MDR marker expression in malignant tumors will 
allow to assess the rationality of chemotherapy pre-
scription and correct the treatment strategy. Due to this 
fact it is topical to study markers of MDR depending 
on the morphological structure and molecular-genetic 
cha racteristics of the primary tumor.
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